Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | In Stock | |
2 mg | $54 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $128 | In Stock | |
25 mg | $237 | In Stock | |
50 mg | $397 | In Stock | |
100 mg | $589 | In Stock |
Description | ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases and improves survival in a murine model. |
In vitro | The co-administration of ATN-161 and 5-FU markedly reduces tumor cell growth more effectively than either treatment alone or the control. Additionally, this combined approach markedly elevates the levels of apoptotic (TUNEL-positive) tumor cells, a result not observed with single-agent treatments. Furthermore, ATN-161 demonstrates a 21% reduction in endothelial cell (EC) numbers after 48 hours compared to controls, highlighting its effectiveness. Importantly, ATN-161 also impedes VEGF-induced endothelial cell migration and capillary formation, although it does not affect their proliferation. It significantly decreases endothelial cell migration towards VEGF in a dose-dependent manner, beginning at 100 nM (P<0.001 vs. VEGF group), showcasing its potential in inhibiting angiogenesis[1][2]. |
In vivo | Initial tests on α5β1-negative human colon cancer xenografts (HT29) show ATN-161 significantly decreases tumor weight and vessel density [1]. Administering ATN-161 post-laser photocoagulation effectively suppresses choroidal neovascularization (CNV) leakage and new blood vessel formation, achieving results comparable to those with AF564 [2]. |
Alias | ATN-161 TFA salt |
Molecular Weight | 711.67 |
Formula | C25H36F3N9O10S |
Cas No. | 904763-27-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: Slightly soluble ![]() |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.